Skip to Content

Alger Health Sciences C AHSCX

Medalist Rating as of | See Alger Investment Hub
  • NAV / 1-Day Return 12.75  /  −0.31 %
  • Total Assets 108.0 Mil
  • Adj. Expense Ratio
    1.950%
  • Expense Ratio 1.950%
  • Distribution Fee Level Average
  • Share Class Type Level Load
  • Category Health
  • Investment Style Mid Growth
  • Min. Initial Investment 1,000
  • Status Open
  • TTM Yield
  • Turnover 306%

USD | NAV as of Apr 19, 2024 | 1-Day Return as of Apr 19, 2024, 10:13 PM GMT+0

Morningstar’s Analysis AHSCX

Will AHSCX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Alger Health Sciences C earns a Morningstar Medalist Rating of Neutral with strength in areas such as People offset by weaker spots such as Process.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings AHSCX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 47.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Amgen Inc

5.49 6.2 Mil
Healthcare

Vertex Pharmaceuticals Inc

5.29 6.0 Mil
Healthcare

Regeneron Pharmaceuticals Inc

5.21 5.9 Mil
Healthcare

Stryker Corp

5.19 5.8 Mil
Healthcare

Eli Lilly and Co

5.08 5.7 Mil
Healthcare

Boston Scientific Corp

5.04 5.7 Mil
Healthcare

Intuitive Surgical Inc

4.19 4.7 Mil
Healthcare

UnitedHealth Group Inc

4.13 4.6 Mil
Healthcare

McKesson Corp

4.06 4.6 Mil
Healthcare

Novo Nordisk A/S ADR

3.73 4.2 Mil
Healthcare